| [1] |
Khan SA,Thomas HC,Davidson BR,et al.Cholangiocarcinoma[J]. Lancet,2005,366(9493):1303-14.
|
| [2] |
Blechacz BR,Gores GJ.Cholangiocarcinoma[J].Clin Liver Dis,2008,12(1):131-50.
|
| [3] |
Chrisanthar R,Knappskog S,Løkkevik E,et al. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel[J].PLoS One,2011,6(4):e19249.
|
| [4] |
Lotan TL,Gurel B,Sutcliffe S,et al.PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostae cancer patients[J].Clin Cancer Res,2011,17(20):6563-73.
|
| [5] |
Sugano N,Suda T,Godai TI,et al.MDM2 gene amplification in colorectal cancer is associated with disease progression at the primary site,but inversely correlated with distant metastasis[J]. Genes Chromosomes Cancer,2010,49(7):620-9.
|
| [6] |
Zhang MF, Zhang ZY, Fu J, et al.Correlation between expression of p53, p21/WAF1,and MDM2 proteins and their prognostic signifi cance in primary hepatocellular carcinoma[J].J Transl Med, 20 09,7:110.
|
| [7] |
Martelli AM, Evangelisti C, Chappell W, et al.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway[J].Leukemia,2011, 25 (7):1064-79.
|
| [8] |
Baig RM,Mahjabeen I,Sabir M,et al.Genetic changes in the PTEN gene and their association with breast cancer in Pakistan[J]. Asian Pac J Cancer Prev,2011,12(10):2773-8.
|
| [9] |
Govender D,Chetty R.Gene of the month:PTEN[J]. J Clin Pathol, 20 12,65(7): 601-3.
|
| [10] |
Skírnisdóttir I,Seidal T. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer[J].Int J Gynecol Cancer,2011,21(6):1024-31.
|
| [11] |
Chung JY,Hong SM,Choi BY,et al.The expression of phospho-AKT, phospho-mTOR,and PTEN in extrahepatic cholangiocarcinoma[J].Clin Cancer Res,2009,15(2):660-7.
|
| [12] |
Noon AP, Vlatkovi? N, Polański R,et al. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?[J]. Cancer, 2010, 116(4):780-90.
|
| [13] |
Sharifi -Sistani N,Zartab H, Babakoohi S,et al.Immunohistochemical comparison of the expression of p53 and MDM2 proteins in ameloblastomas and keratocystic odontogenic tumors[J].J Craniofac Surg,2011,22(5):1652-6.
|
| [14] |
Cui JJ,Han XL,Wang WM.Expression and signifi cance of p53 and mdm2 in patients with leukoplakia cancer[J].Asian Pac J Trop Med,2013,6(10):831-4.
|
| [15] |
Epistolato MC,Disciglio V,Livide G,et al.p53 Arg72Pro and MDM2 309 SNPs in hereditary retinoblastoma[J].J Hum Genet, 20 11,56(9):685-6.
|
| [16] |
Jarnagin WR,Klimstra DS,Hezel M,et al.Differential cell cycleregulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome[J]. J Clin Oncol,2006,24(7):1152-60.
|
| [17] |
Li Y,Guessous F,Kwon S,et al.PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations[J]. Cancer Res,2008,68(6):1723-31.
|
下载:
